02:09 PM EDT, 03/20/2025 (MT Newswires) -- Revvity ( RVTY ) said Thursday it has signed a new agreement with Genomics England to further collaborate on the Generation Study, a national initiative to screen up to 100,000 newborns for more than 200 rare genetic disorders.

Under the new contract, Revvity ( RVTY ) said it will also provide DNA sequencing services to help screen newborns for rare genetic conditions, adding to its previous DNA extraction services.

The firm said it will now be able to provide an end-to-end solution with a localized lab facility to advance the screening process.

Price: 107.11, Change: -2.81, Percent Change: -2.56